


054.00021



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Matalon)
Serial No.: 10/826,112)
Filed: April 17, 2004) Examiner: Unknown
For: METHODS AND MATERIALS FOR TREATING)
CONDITIONS ASSOCIATED WITH)
METABOLIC DISORDERS)
Art Unit: 1614

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97-1.98

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


Dear Sir:

Pursuant to 37 C.F.R. §§ 1.97-1.98, applicant hereby brings to the attention of the United States Patent and Trademark Office ("PTO") the references listed on the attached PTO-1449 form. Copies of foreign patent documents and non-patent literature listed on the attached PTO-1449 form are enclosed.


An English-language summary is provided at the end of the foreign-language reference Martyniuk et al, "Restoration of the Potential-dependent L-Phenylalanine-Induced Calcium Current by L-Tyrosine in Cultured Hippocampal Neurons," Neurofiziologia (Russian), 23(2):245-247 (1991).

In the event that a fee is necessary in connection with the filing of this statement, the Director is authorized to charge Deposit Account No. 50-0772 for any such fee. A duplicate copy of this paper is enclosed.

Dated: August 12, 2004


Peter Rogalskyj
Reg. No. 38,601

Rogalskyj & Weyand, LLP
P.O. Box 44
Livonia, New York 14487-0044
Tel: 585-346-1004
Fax: 585-346-1001

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.	
8-12-04	
Date	Peter Rogalskyj

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)


Docket Number (Optional)
054.00021

Application Number
10/826,112

Applicant(s)
Matalon

Filing Date
April 17, 2004

Group Art Unit
1614



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1	4,209,531	06/24/1980	Berry			
	2	4,252,822	02/24/1981	Berry			

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

3	Oldendorf, "Measurement of Brain Uptake of Radiolabelled Substances Using a Tritiated Water Internal Standard," <u>Brain Res.</u> , 24(2):372-376 (1970)
4	Andersen et al., "Lowering Brain Phenylalanine Levels by Giving Other Large Neutral Amino Acids. A New Experimental Therapeutic Approach to Phenylketonuria," <u>Arch. Neurol.</u> , 33(10):684-686 (1976)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

P09A/REV05

Patent and Trademark Office • U.S. DEPARTMENT OF COMMERCE

SHEET 1 OF 3

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Docket Number (Optional)
054.00021

Application Number
10/826,112

Applicant(s)
Matalon

Filing Date
April 17, 2004

Group Art Unit
1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

*EXAMINER
INITIAL

5

Kaufman, "Phenylketonuria: Biochemical Mechanisms," pp. 1-132 in Agranoff et al., eds, Advances in Neurochemistry, New York: Plenum Press (1977)

6

Pardridge, "Blood-Brain Barrier Amino Acid Transport: Clinical Implications," pp. 87-99 (chapter 6) in Cockburn et al., eds. Inborn Errors of Metabolism in Humans, Lancaster, England: MTP Press Ltd. (1982)

7

Lou, "Large Doses of Tryptophan and Tyrosine as Potential Therapeutic Alternative to Dietary Phenylalanine Restriction in Phenylketonuria," Lancet, 2(8447):150-151 (1985)

8

Berry et al, "Valine, Isoleucine and Leucine. A New Treatment for Phenylketonuria," Am. J. Dis. Child., 144:539-543 (1990)

9

Hidalgo et al., "Transport of a Large Neutral Amino Acid (Phenylalanine) in a Human Intestinal Epithelial Cell Line: Caco-2" Biochim. Biophys. Acta, 1028(1):25-30 (1990)

10

Martyniuk et al, "Restoration of the Potential-dependent L-Phenylalanine-Induced Calcium Current by L-Tyrosine in Cultured Hippocampal Neurons," Neurofiziologia (Russian), 23(2):245-247

11

Kaufman, "Some Facts Relevant to a Consideration of a Possible Alternative Treatment for Classical Phenylketonuria," J. Inher. Metab. Dis., 21(supplement 3):4 (1998)

12

Pardridge, "Blood-Brain Barrier Carrier-Mediated Transport and Brain Metabolism of Amino Acids," Neurochem. Res., 23(5):635-644 (1998)

13

Pietz et al., "Large Neutral Amino Acids Block Phenylalanine Transport into Brain Tissue in Patients with Phenylketonuria," J. Clin. Invest., 103(8):1169-1178 (1999)

14

Zielke et al., "LNAs Auto-Exchange When Infused by Microdialysis Into the Rat Brain: Implication for Maple Syruin Urine Disease and Phenylketonuria," Neurochem. Int., 40(4):347-354 (2002)

15

Koch et al., "Large Neutral Amino Acid Therapy and Phenylketonuria: A Promising Approach to Treatment," Molecular Genetics and Metabolism, 79:110-113 (2003)

16

Matalon et al., "Future Role of Large Neutral Amino Acids in Transport of Phenylalanine into the Brain," Pediatrics, 112(6 Pt 2):1570-1574 (2003)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)
054.00021

Application Number
10/826,112

Applicant(s)
Matalon

Filing Date
April 17, 2004

Group Art Unit
1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

*EXAMINER
INITIAL

17

Ahring et al., "Benefits of Using PreKUnil Tablets as Treatment for Adults with PhenylKetonUria (PKU) in Denmark,"
http://www.nilab.dk/pdf/prekunil_treatment.pdf (date unknown)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.